Status:
UNKNOWN
A Pharmacokinetics Study of Daptomycin in Critically Ill Patients and Effects of Daptomycin on Kidney
Lead Sponsor:
Zhongnan Hospital
Conditions:
Outcome, Fatal
Infection
Eligibility:
All Genders
18-65 years
Brief Summary
Daptomycin ，is the first approved member of a new class of antimicrobials, the cyclic lipopeptides, and presents selective action against gram-positive bacteria, including methicillin- and vancomycin-r...
Eligibility Criteria
Inclusion
- Patients with severe bloodstream infections eligible for daptomycin indications
- Treatment in the ICU
- Patients aged 18 to 65
Exclusion
- Pregnant and lactating women
- The patient or his agent refused to participate in the trial
- Incomplete clinical medical information
- Patient participates in another clinical trial at the same time
- Previous history of myopathy or current CPK increase more than 2 times than normal
- Patients need to use warfarin anticoagulation
- Patients use tobramycin for anti-infection
- Patients use drugs such as cyclosporine and fibrates that can cause adverse reactions to muscle disease
- Patients with Gram-negative bacterial infections caused by abdominal and respiratory infections
- Patients with heart failure, respiratory failure, Glasgow coma index (GCS) ≤ 8 points, liver function CHILD PUGH score C that are not related to the infection
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04277143
Start Date
December 1 2020
End Date
December 31 2022
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430000